Abstract
Inhalation drug delivery systems (IDDS) have emerged as a pivotal route for administering drugs directly to the lungs, enabling rapid onset of action and reducing systemic side effects. Technological advancements in inhalers, nebulizers, and dry powder formulations have enhanced drug targeting, bioavailability, and patient adherence. This article reviews the progress made in inhalation drug delivery, highlighting innovations in device design, formulation technologies, and clinical applications, especially for respiratory diseases like asthma and COPD. Furthermore, it explores the current challenges related to device handling, formulation stability, and drug deposition efficiency.
All articles published in the American Journal of Pharmacy and Pharmacology are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows others to:
-
Share — copy and redistribute the material in any medium or format
-
Adapt — remix, transform, and build upon the material for any purpose, even commercially
Under the following terms:
-
Attribution — Appropriate credit must be given to the original author(s) and source, a link to the license must be provided, and any changes made must be indicated.
By submitting their work, authors agree to these licensing terms and retain copyright of their articles.